Psychedelic Virtual Reality

This observational trial (n=15) will evaluate a novel Virtual Reality Psychedelic (VRP) called DeepDream using the Meta Quest 3 device.

The study, scheduled to run from September 2024 to March 2025, aims to determine whether the subjective experience of DeepDream VRP is comparable to a standard dose of psychedelics. Researchers will also compare DeepDream VRP to other available VR modalities designed to mimic psychedelic experiences and assess the incidence of VRP adverse effects.

The study will involve healthy volunteers and focus on psychedelic experiences in a virtual reality context. As an observational study, it will provide valuable insights into the potential use of virtual reality in psychedelic research or clinical practice, potentially offering a non-pharmacological alternative for inducing psychedelic-like experiences.

Trial Details

The primary objective of this study is to determine whether the subjective experience of a novel VRP (DeepDream) will be comparable to a standard dose of psychedelics. This study also looks to compare the subjective experience of DeepDream VRP to other available VR modalities developed to mimic psychedelic subjective experience along with assessing the incidence of VRP adverse effects.

NCT Number NCT06581263

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.